Background
Adult mammalian hearts have extremely limited regenerative capacity after myocardial infarction (MI). The epicardium — the outer layer of the heart — is a progenitor cell reservoir during fetal development but becomes quiescent in adult life. Smart and colleagues at King’s College London discovered that thymosin β4 (Tβ4) could reactivate these dormant epicardial progenitors in adult mice, potentially offering a regenerative strategy for ischemic heart disease.
This study represented a landmark advance in cardiac regeneration biology, demonstrating that a naturally occurring peptide could unlock dormant developmental programs in the adult heart.
Methods
Adult C57BL/6 mice were treated with Tβ4 (6 µg/day IP) for 1 week before surgically induced myocardial infarction (left anterior descending artery ligation), then continued for 2 weeks after MI. Controls received vehicle.
Outcomes measured:
- Epicardial cell lineage tracing (Cre-lox system) to track progenitor cell fate
- Cardiac function: echocardiography (ejection fraction, fractional shortening)
- Histology: cardiomyocyte number, capillary density at infarct border zone
Key Findings
Epicardial Progenitor Reactivation:
- Tβ4 priming caused proliferation and epithelial-to-mesenchymal transition of adult epicardial cells
- Lineage tracing confirmed these progenitors differentiated into: cardiomyocytes (de novo), vascular smooth muscle cells, and cardiac fibroblasts
Functional Cardiac Outcomes:
- Tβ4-primed mice showed significantly better preserved ejection fraction at 4 weeks post-MI
- Infarct size was smaller; border zone had greater cardiomyocyte density
- Capillary density in the border zone was 40% higher in Tβ4-treated mice
Mechanism:
- Tβ4 reactivated the embryonic epicardial transcription factor Wt1 in adult epicardium
- This restored the developmental competence lost in adult tissue — a form of epigenetic reprogramming rather than de novo stem cell injection
Clinical Significance
This Nature paper established that TB-500 (Tβ4) is not simply a repair/anti-inflammatory peptide but a bona fide cardiac regeneration signal capable of:
- Reactivating endogenous progenitors: No exogenous stem cells required — Tβ4 mobilizes the heart’s own reserve capacity
- Multi-lineage differentiation: Progenitors became both new cardiomyocytes and supporting vasculature — two essential components for functional repair
- Ischemic heart disease: These findings triggered human clinical trial interest in Tβ4 as an injectable adjunct to MI treatment
The discovery reshaped understanding of TB-500/Tβ4 from a wound-healing peptide to a developmental reprogramming signal.
Limitations
- Mouse model — human epicardial progenitor biology may differ substantially
- Pre-treatment required for maximal effect; post-MI-only treatment showed reduced benefit
- Long-term cardiac function outcomes (beyond 4 weeks) were not assessed
- Cardiomyocyte differentiation efficiency was modest; fully functional contractile unit integration remains a challenge